FDA expands use of Kisqali to early stage breast cancer patients
Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.
Pharmaceutical Technology on MSN2 天
FDA expands Novartis’ Kisqali label to include early breast cancer patients
Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...
Kisqali wins FDA nod for breast cancer treatment: Dosage, effectiveness and side effects of ...
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...
FDA expands approval of breast cancer drug Kisqali to earlier stage patients
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to treat patients with earlier stage cancer, ...
biopharma-reporter2 天
Novartis’ Kisqali receives FDA approval to reduce the risk of breast cancer recurrence
Novartis announced this week that the FDA has approved ribociclib (marketed as Kisqali) for the treatment of people with ...
Cure Today2 天
Kisqali Plus Aromatase Inhibitor Shows Benefits in HR+/HER2- Breast Cancer
Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free ...
scrippsnews2 天
Breast cancer drug Kisqali gets FDA approval to prevent cancer recurrence
The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce ...
FiercePharma3 天
Novartis heaps pressure on Lilly with broad FDA approval for Kisqali in early breast cancer
An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...
pharmaphorum3 天
Lilly on alert as new Kisqali approval threatens Verzenio
Verzenio was approved for a similar adjuvant indication last year, having been used for a couple of years only in patients ...
The Pharma Letter2 天
Novartis’ Kisqali cleared for expanded indication by FDA
The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) ...
China Internet Information Center2 天
FDA aprueba nuevo tratamiento contra el cáncer de mama en etapas tempranas
La Administración de Alimentos y Medicamentos de Estados Unidos (FDA) otorgó el martes la aprobación al uso de ribociclib adyuvante (Kisqali) en combinación con un inhibidor de la aromatasa, destinado ...
Novartis’ Kisqali gets expanded FDA OK; Mene Pangalos joins Omega Funds
The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic ...